Pharma RSS Digest - 2026-08-13
Overview
A measured session on the pharma tape was driven by company-specific updates rather than broad sector themes. Regulatory milestones spanned two geographies, with ArkBio clearing a China IND for an influenza Fc-conjugate and PTC Therapeutics adding a U.S. BLA-stage gene therapy to its rare disease portfolio. INOVIO delivered a quarterly update that keeps its October PDUFA date squarely in focus, while a nationwide recall of a widely used biosimilar underscored ongoing sterility-quality scrutiny in injectable manufacturing. Capital markets activity was thin, with no major financing or read-through cross-currents.
Key Developments
ArkBio secured China NMPA approval for its IND application for AK0406, a long-acting antiviral Fc-conjugate designed for influenza prophylaxis. The candidate is the first influenza AFC to enter clinical development in China and combines a small-molecule antiviral with an antibody Fc fragment to enable sustained pre- and post-exposure protection. Parallel development is underway, with all cohorts already dosed in an Australian Phase I trial and a domestic China pathway planned with the CDE. The next markers to watch are safety and pharmacokinetic readouts from the Australian follow-up, along with any timeline disclosure for first-in-China dosing.
INOVIO used its second-quarter update to confirm that the FDA has completed late-cycle review meetings and pre-licensure inspections for INO-3107, its lead candidate for recurrent respiratory papillomatosis, with a PDUFA target action date of October 30, 2026. The company also highlighted positive Phase 3 topline data from partner ApolloBio for VGX-3100 in cervical dysplasia in Greater China. Quarterly net loss narrowed materially, though the improvement was largely driven by a non-cash warrant fair value adjustment rather than operating gains, and cash runway now extends only into late Q1 2027. The October PDUFA decision, along with forthcoming FDA feedback on confirmatory trial design, is the central near-term catalyst.
PTC Therapeutics was named the winning bidder for ST-920, a BLA-stage AAV gene therapy for Fabry disease, in Sangamo Therapeutics' bankruptcy auction. PTC will pay $111 million upfront plus up to $100 million in regulatory milestones, with a rolling BLA submission targeted for completion in Q4 2026 and a potential 2027 launch. Phase 1/2 STAAR data showed favorable renal function trends and enabled enzyme replacement therapy withdrawal in all baseline ERT patients, supporting potential differentiation in a market of roughly 11,000 U.S. patients. Investors should monitor bankruptcy court approval, antitrust review, and final closing in late Q3 or early Q4 2026, along with the BLA module completions.
Watchlist
- Fresenius Kabi issued a nationwide user-level recall of one lot of Tyenne (tocilizumab-aazg) 400 mg/20 mL injection due to glass particle contamination, with potential risks including blood clots and pulmonary embolism; no adverse events have been confirmed in the announcement, but root cause and any additional lot impacts remain undisclosed. [link]
- Talphera reported its NEPHRO CRRT registrational study of Niyad is 75% enrolled, with completion targeted by year-end 2026, alongside a 21% upward revision to projected U.S. CRRT procedure volumes and positive draft KDIGO guideline inclusion. [link]
- Alexandria Real Estate Equities priced $1 billion of junior subordinated notes due 2057, a biotech-adjacent real estate financing that was suppressed from the main digest for being too thin to interpret on its own. [link]
- Two items outside the core pharma universe (Anytime Fitness's acquisition of INTERVAL Sport Fitness and U.S. News & World Report's 2026-2027 Pet Insurance Awards) circulated on the same wire but were not material to the pharma sector. [link]